Compugen (NASDAQ:CGEN) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Compugen Ltd. (NASDAQ:CGEN)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.64 and traded as high as $1.80. Compugen shares last traded at $1.79, with a volume of 238,976 shares.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CGEN shares. Wall Street Zen upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright assumed coverage on Compugen in a report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $4.00.

Compugen Price Performance

The business’s 50-day simple moving average is $1.75 and its two-hundred day simple moving average is $1.64.

Institutional Trading of Compugen

Several institutional investors have recently bought and sold shares of CGEN. Jane Street Group LLC raised its stake in shares of Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after buying an additional 359,785 shares during the period. ARK Investment Management LLC increased its holdings in Compugen by 20.6% in the 2nd quarter. ARK Investment Management LLC now owns 1,072,776 shares of the biotechnology company’s stock worth $1,785,000 after acquiring an additional 183,107 shares in the last quarter. XTX Topco Ltd purchased a new stake in Compugen in the 4th quarter worth $104,000. Marshall Wace LLP raised its position in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the period. Finally, WINTON GROUP Ltd purchased a new position in Compugen during the fourth quarter valued at $84,000. 12.22% of the stock is owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.